• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Reed-Lane

    Flow Sciences

    PCI Pharma Services

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Alcami

    Adare Pharma Solutions

    Baxter BioPharma Solutions

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

    A strong trend in drug substance and drug product biomanufacturing, as is for formulation, is that of increasing therapeutic complexity.

    **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production
    **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production
    Figure 1: Rentschler Biopharma’s strategic alliance with Leukocare is tailored to client needs.
    **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production
    Figure 2: The Leukocare workflow for optimized formulation development.
    **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production
    Figure 3: Aggregation Propensity demonstrated by the measurement of monomer fraction by SE-HPLC (Size-Exclusion High Performance Liquid Chromatography) of best performing formulations generated by Leukocare (Leukocare formulation 1 / 2) and client formulation (original formulation).
    **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production
    Figure 4: Aggregation Propensity demonstrated by the measurement of monomer fraction by SE-HPLC (Size-Exclusion High Performance Liquid Chromatography) of best performing formulations generated by Leukocare (Leukocare formulation 1 / 2) and client formulation (original formulation).
    **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production
    Figure 5: Short-term stability study at 5°C & 25°C showing improvement of stability (here: measured by SE-HPLC of best performing formulation generated by Leukocare (‘Leukocare formulation’) as compared to reference formulation (‘Reference formulation’).
    Latika Bhonsle-Deeng, Rentschler Biopharma SE, and Konstantin Petropoulos, LEUKOCARE AG10.14.20
    A strong trend in drug substance (DS) and drug product (DP) biomanufacturing, as is for formulation, is that of increasing therapeutic complexity. These challenges of evolving sophistication take on a new meaning in an ever rapidly changing biopharmaceutical landscape. Solving the complex challenges of tomorrow, calls for innovative mindsets, technological advancement, and proficient and complementary expertise. This need led to the forging of the strategic alliance between biomanufacturing expert Rentschler Biopharma SE and formulation specialist Leukocare AG (Figure 1).


    Figure1. Rentschler Biopharma’s strategic alliance with Leukocare is tailored to client needs.

    Leukocare is a top formulation development specialist in services tailored to client needs. Rentschler Biopharma SE is a leading global contract development and manufacturing organization (CDMO) renowned for its excellent process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Both companies have been collaborating since February 2017, to offer biologics and biosimilar makers a competitive edge through significantly stabilized end products. Leukocare is the specialized technology partner and the exclusive formulation developer for Rentschler Biopharma’s biopharmaceutical development and biomanufacturing business. By combining well established scientific know-how and a commitment to high-quality, this strategic alliance leaves no stone unturned for the benefit of clients and their patients. Till date, the alliance has provided numerous clients with tremendous commercial advantage, by leveraging high-quality formulation developments.

    The coming together of world-class capabilities in formulation development and high-quality biomanufacturing is a unique constellation. This alliance leverages technological leadership and longstanding experience, for best-in-class project delivery for all of its clients. Ultimately, the incorporation of early formulation development can further enhance a robust and highly productive manufacturing process. This in turn, strengthens/adds to the overall efficiency of the process and maximizes product potential. The manifold advantages include shorter development timelines, cost savings, extra intellectual property (IP) protection in form of patents, leading to a competitive edge for client products and outstanding services (Figure 2).


    Figure 2. The Leukocare workflow for optimized formulation development.

    Strategic alliances to strengthen capabilities
    Rentschler Biopharma has always run a different race. Companies offering complementary services are not seen as competition, rather as an opportunity to evolve through collaboration. Rentschler Biopharma has always aimed to offer its clients the best-available and best-fit solutions possible. Hence, the company seeks out strategic alliances with other organizations that have world-class capabilities and seamlessly integrates their offerings into Rentschler Biopharma’s processes. The entire process is coordinated and managed by the CDMO, thus ensuring that all parts of the project are aligned. Both teams work closely together like one unit, embodying close collaboration and full transparency at every step of the project.

    The alliance partners continue to conduct their own business interactions and further develop their knowledge and offerings, which in turn creates more value for all stakeholders. With this approach, strategic alliances extend the world-class service portfolio offered by Rentschler Biopharma, while driving further innovation within the company. A glowing example is the successful strategic alliance with Leukocare.

    Early stage formulation maximizes API potential
    Rentschler Biopharma is the first and only CDMO to have access to Leukocare’s patented SPS® formulation technologies. The contribution of early stage formulation development, to successful therapeutic commercialization is often underestimated. Formulation issues are known to often cause significant delays during clinical development and towards commercialization eventually leading to project failure. Thus, a clearly mapped out formulation strategy at the early stage of the product development is vital to project success. The deployment of a tailored and potentially commercially viable formulation early in the process offers many significant gains. It enables (i) reduced time to market, (ii) higher probability of success as well as (iii) added advantages due to IP that further add to a product’s competitive edge.

    Leukocare and Rentschler Biopharma’s strategic alliance partnership for formulation development, combines bioinformatics and an algorithm- and database-driven approach for drug product stabilization. This tactic helps to explore a broader design space as compared to conventional approaches, so that it strongly increases the probability of success, avoiding high-throughput-screening, thus saving precious drug substance material. Moreover, it improves the stability and quality of biologics such as antibodies at all concentrations and vaccines, including live viral vectors, in liquid and dry formulation. Furthermore, it protects proteins in biologically functionalized medical devices.

    Firstly, Leukocare’s technologies prevent molecule degradation and potentially improve storage at room temperature (or even higher temperatures) by increasing thermal stability of protein therapeutics. Secondly, many biopharmaceuticals have to be lyophilized for stability reasons, today. The transfer of lyophilized to liquid formulations (i) facilitates the reduction of manufacturing costs, (ii) adds convenience in administration and (iii) avoids any loss of therapeutic efficacy and activity during the lyophilization process.

    Client-focused solutions for the win
    Since the last three years, the alliance has worked on diverse projects. This diversity stems from the type of molecule, the specific needs of every client and the overall project expectations. Every molecule, every project and every client are unique. Key to the success of the Rentschler Biopharma/Leukocare alliance has been the implementation of tailored approaches, that have been customized for every project.

    This leads to optimal solutions for clients. While the optimal solution for one client could mean delivering a fast track formulation within a fixed timeframe for an early clinical stage project, it could also translate into best-in-class formulations including IP protection with market advantages for another client. A third client might need problem-solving on existing formulation towards a better solution. Thus, four project case studies are presented here, which will shed light on these very diverse aspects.

    Case 1
    The first project aimed to optimize an existing formulation for a clinical stage therapeutic protein. The key deliverable to the client in this project, was the exchange of one specific excipient in the formulation while retaining product stability. In an ideal scenario, the exchange of the excipient would contribute to further improving stability. This challenge was mastered by an in-depth data analysis, resulting in a better understanding of the weak structural spots and the degradation of the specific protein. This information was used to identify tailored formulation variants. These tailored variants were developed keeping in mind both, (i) client requirements, that is the exchange of the unwanted excipient, as well as (ii) further improvement of the stability of the protein stability. Ultimately, the protein’s stability was significantly improved in comparison to the original formulation as demonstrated by the measurement of aggregation propensity (Figure 3).


    Figure 3. Aggregation Propensity demonstrated by the measurement of monomer fraction by SE-HPLC (Size-Exclusion High Performance Liquid Chromatography) of best performing formulations generated by Leukocare (Leukocare formulation 1 / 2) and client formulation (original formulation).

    Case 2
    The formulation development during the second project pertained to a designer molecule that was in preparation to enter clinical studies. The client requested for a formulation that would push the envelope and go beyond industry standards and allow for long term liquid storage at 2-8°C for the therapeutic. Furthermore, it was important to control both the number and the amount of excipients, in order to manage formulation complexity and cost of goods in mind. At the same time, the novel formulation should potentially create new IP, adding further commercial value to the therapeutic. Leukocare’s database and algorithm-based formulation approach were implemented in this project, to sequentially improve formulation candidates, leading to high stability. This ultimately resulted in the best-suitable liquid storage formulation for the candidate molecule. Key to the success of this project was Leukocare’s in-depth expertise in stabilizing effects, related to a multitude of excipients, relevant for the stabilization of biologics such as amino acids and a combination of the same.  The implementation of formulation development know-how in downstream processing of this molecule resulted in increased product yield as well. This elegantly reflects the strength of this alliance and the immense benefits of the close collaboration for our clients (Figure 4).


    Figure 4. Short-term stability study at 5 degrees Cesius and 25 degrees Celsius showing improvement of stability (here: measured by SE-HPLC of best performing formulation generated by Leukocare ('Leukocare formulation') as compared to reference formulation ('Reference formulation').

    Case 3
    The formulation for a monoclonal antibody based on ‘industry standard formulations’, whilst delivering superior stability, was the focus of the third project. While applying the database supported and algorithm-based formulation approach, the development focus was essentially on standard excipients and combinations thereof. The project’s success can be attributed to Leukocare’s deep expertise in the optimal application of Design of Experiments (DoE), even in a limited formulation development design space. Software-based readouts by linear and non-linear statistics enabled the most predictive selection of highly stable formulations to choose from for the molecule candidate (Figure 5). 


    Figure 5. Short-term stability study at 5 degrees Celsius and 25 degrees Celsius (here: measure by SE-HPLC) of best performing formuation generated by Leukocare ('Leukocare formulation')

    Case 4
    The fourth project brought with it yet another challenge. A liquid formulation with standard requirements - stable at 2-8°C for intravenous (IV) injection, drug product concentration 50 mg/ml) for a monoclonal antibody was to be delivered. At the same time, the formulation had to allow room for further development of a high-concentration formulation to enable subcutaneous (SC) injection at a later stage of the project. Hence, a combination of excipients, having the potential to generate higher concentrations of the monoclonal antibody formulation for SC application was considered and implemented from the very start of the project. Similar to the previous project, the biostatistical preparation and analysis of application of in-depth biostatistics for optimal DoE generated data stood the experts in good stead.

    Additionally, Leukocare’s vast expertise in high concentration formulations was vital for this project’s success. A large number of highly stable formulations were created by the client. Moreover, the formulation continued to display comparable stability, even after the producing cell line clone was changed. At the same time, bridging studies - low (50 mg/ml) versus high (150 mg/ml) concentrated formulation—confirmed the very low aggregation propensity and low viscosity (< 7 mPa·s), potentially allowing even higher concentrations of the formulation. This clearly emphasizes the technological competence and know-how in simplifying clients’ complex challenges.

    Leveraging technological leadership for clients and patients
    Since 2017, the Leukocare/Rentschler Biopharma alliance has consistently aimed at exceeding client expectations with the goal of offering best-fit solutions while bringing essential therapeutics to market more easily and faster. This is attributable to the expert teams from both organizations, that work together like one unit. This seamless collaboration is fueled by continuous communication and transparency to the client. Scientific expertise, an innovative mindset, the ability to think outside the box—all of these attributes contribute immensely to this successful alliance. At the core is the strong commitment to driving the translation of medical research into outstanding treatments—for clients and their patients all over the globe. 


    Dr. Latika Bhonsle-Deeng studied Biomedical Sciences at the University of Delhi, India. During her PhD thesis at the Max-Planck-Institute of Neurobiology, Munich, she investigated the autoimmune disease multiple sclerosis. She then consulted international companies, focusing on strategic projects in corporate finance and healthcare. She is an expert in scientific communication, having worked as a freelance journalist, specializing in European life sciences. Since 1st November 2019, Dr. Bhonsle-Deeng has been Manager Corporate Communication at Rentschler Biopharma SE.

    Dr. Konstantin Petropoulos is VP & Head of Business Development, Marketing & Sales at LEUKOCARE with more than 10 years of experience in the biotech & pharma industry. Prior to joining LEUKOCARE, Konstantin held different positions with increasing responsibility at Bayer AG & MorphoSys AG. He holds a PhD in Molecular Biology from the Ludwig-Maximilians-University Munich and an MBA from the FOM University of Applied Sciences.
    Related Searches
    • Formulation Development

    Related Features

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Formulation Development
      Developing Faster-to-Clinic Formulations

      Developing Faster-to-Clinic Formulations

      When standard formulation strategies fail, is there a fast path to clinic for hard-to-formulate therapeutics?
      Phil Morton, Chief Technology Officer, Albumedix 06.12.18

    • Formulation Development
      Formulation Development Trends

      Formulation Development Trends

      Innovation in formulation development continues to be driven by the need to improve drug bioavailability.
      Torkel Gren, General Manager, Recipharm Pharmaceutical Development AB 04.10.18


    • Formulation Development | Preclinical Outsourcing
      Formulating Candidates  with Bioavailability Issues

      Formulating Candidates with Bioavailability Issues

      To avoid the solubility pitfalls that too often halt a medicines progress from clinic to market, it’s vital to start formulat
      Stephen Tindal, Director - Science and Technology, Catalent 05.09.17

    • Drug Development | Formulation Development
      Formulation Strategies for  Aging Consumers

      Formulation Strategies for Aging Consumers

      Convenience, flavor and novel combinations of ingredients can help offer better product experiences.
      Stephen Tindal, Director, Science and Technology, Catalent Pharma Solutions 03.07.17

    • Drug Development | Formulation Development
      Modeling & Simulation for  Drug Development & Formulation

      Modeling & Simulation for Drug Development & Formulation

      A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.
      Nathan Teuscher and Nikunjkumar Patel , Certara 03.07.17


    • APIs | Clinical Trial Materials | Clinical Trials | Drug Development | Formulation Development
      Choosing Oral Formulations for First-in-man Clinical Trials

      Choosing Oral Formulations for First-in-man Clinical Trials

      Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems
      Jon Sutch, Senior Manager of Formulation Development, Patheon 10.11.16

    • Biosimilars | Clinical Trials | Formulation Development
      Critical Steps for Biosimilar Assessment

      Critical Steps for Biosimilar Assessment

      Establishing “finger-print like” biosimilarity prior to the clinic
      Fiona Greer, SGS 05.05.16

    • Capsules | Clinical Trials | Excipients | Formulation Development | Serialization
      The Evolution of the ‘One-Stop Shop’  in Clinical Supplies Sourcing

      The Evolution of the ‘One-Stop Shop’ in Clinical Supplies Sourcing

      What does a one-stop shop really mean and is it always best for the client?
      Paul Skultety, Alex McClung, Ted Koontz and Damian Gant, Xcelience, a division of Capsugel Dosage Form Solutions 05.05.16


    • APIs | cGMP Manufacture | Drug Development | Facilities | Formulation Development | Supply Chain

      Newsmakers: Ian Muir

      End-to-End Service
      Tim Wright, Editor 04.05.16

    • Capsules | cGMP Manufacture | Clinical Trials | Drug Development | Drug Discovery | Excipients | Facilities | Formulation Development
      Solid Dispersions

      Solid Dispersions

      A universal formulation strategy for poorly soluble drugs?
      Robert Harris, Juniper Pharma Services 04.05.16

    • Capsules | Chemistry | Extractables and Leachables | Fill/Finish | Formulation Development | Supply Chain

      Newsmakers: Hanns-Christian Mahler

      Head of drug product services talks about Lonza’s new capabilities
      Tim Wright, Editor 03.09.16


    • APIs | Biosimilars | Drug Delivery | Drug Development | Fill/Finish | Formulation Development | Lyophilization | Parenterals | Supply Chain
      Parenteral Outsourcing Trends

      Parenteral Outsourcing Trends

      Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing market
      Tim Wright, Editor 03.09.16

    • APIs | Capsules | Chemistry | Drug Delivery | Excipients | Formulation Development | Serialization | Supply Chain
      Solid Dosage Outsourcing Trends

      Solid Dosage Outsourcing Trends

      The market continues to evolve as blockbusters are replaced by more targeted treatments that have unique requirements.
      Tim Wright, Editor 03.09.16

    • APIs | Capsules | Clinical Trials | Drug Delivery | Excipients | Formulation Development
      Developing Palatable Drug Products

      Developing Palatable Drug Products

      A decision framework and guide for CDMOs
      Jeff Worthington and David Tisi, Senopsys LLC 03.09.16

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login